Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 8.18 (-0.11), NPSP: 31.28 (-0.99), AMGN: 164.53 (-1.55), NKTR: 15.31 (-0.29)
Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer
PR Newswire - Thu Dec 11, 5:00PM CST
Nektar Therapeutics (NASDAQ: NKTR) today presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102) which collected and analyzed circulating tumor cell (CTC) samples from patients in the study. A total of 80% of the 852 patients enrolled in the BEACON trial participated in the CTC sub-study. Among the 627 patients who participated and had evaluable baseline samples, CTCs were detected in 97% of these samples.
NKTR: 15.31 (-0.29)
Nektar/AstraZeneca's Moventig Gets EU Approval for OIC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 5:50PM CST
Nektar (NKTR) and AstraZeneca's Moventig gained EU approval for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxatives.
BAX: 71.77 (-1.34), AZN: 71.80 (-1.80), SCMP: 13.93 (-0.13), NKTR: 15.31 (-0.29)
Nektar Therapeutics Shares Up 15.9% Since SmarTrend's Buy Recommendation (NKTR)
Comtex SmarTrend(R) - Wed Dec 10, 11:07AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 1 month, Nektar Therapeutics has returned 15.92% as of today's recent price of $15.91.
NKTR: 15.31 (-0.29)
MOVENTIG® Approved In The European Union For Opioid-Induced Constipation
PR Newswire - Tue Dec 09, 7:00AM CST
Nektar Therapeutics (NASDAQ:NKTR) reported partner AstraZeneca today announced that MOVENTIG® (naloxegol) has been granted Marketing Authorisation by the European Commission (EC) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved in the European Union (EU).
NKTR: 15.31 (-0.29)
Moventig cleared in Europe for OIC
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 6:14AM CST
SGYP: 2.93 (-0.05), PGNX: 7.10 (+0.16), CBST: 96.31 (+0.04), AZN: 71.80 (-1.80), SLXP: 103.36 (-2.79), NKTR: 15.31 (-0.29)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 11:45AM CST
GLOG: 18.48 (+0.74), MILL: 1.24 (unch), LPHI: 0.94 (-0.06), NEOT: 7.49 (-0.48), BOBE: 50.51 (+0.21), FES: 1.17 (+0.01), REDF: 2.14 (-0.04), NKTR: 15.31 (-0.29), PRTO: 9.79 (-0.07), CANF: 3.49 (+0.03), CALI: 1.26 (-0.09), TRT: 3.08 (+0.08), SQNM: 3.67 (-0.11), CARB: 13.67 (-0.28), SEED: 1.29 (-0.02), BLFS: 1.81 (-0.01), DGLY: 15.55 (+1.34), TCCO: 4.73 (-0.03), ALCO: 42.15 (-0.53), PBYI: 196.34 (-7.66)
Nektar Therapeutics Up 17.2% Since SmarTrend Uptrend Call (NKTR)
Comtex SmarTrend(R) - Wed Dec 03, 9:41AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 1 month, Nektar Therapeutics has returned 17.16% as of today's recent price of $16.08.
NKTR: 15.31 (-0.29)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 118.55 (-2.23), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93), NKTR: 15.31 (-0.29), AGN: 208.47 (-2.67), IPXL: 31.16 (-0.74), ALDR: 25.27 (-1.46), QCOR: 93.60 (+1.52), MRK: 57.72 (-1.62), TSPT: 1.70 (-0.04), RVNC: 17.45 (-0.23), POZN: 9.12 (-0.08)
Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 104.43 (-2.29), RVNC: 17.45 (-0.23), CLTX: 5.24 (-0.06), GSK: 42.42 (-0.93), NKTR: 15.31 (-0.29), NVS: 93.52 (-0.82)
Baxter Files BLA for BAX 855 in Hemophilia A Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 11:40AM CST
Baxter International Inc (BAX) recently filed a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) for the approval of BAX 855.
ICUI: 80.95 (-1.04), BAX: 71.77 (-1.34), NKTR: 15.31 (-0.29), OSUR: 9.49 (-0.25)
Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
PR Newswire - Mon Dec 01, 8:18AM CST
Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
NKTR: 15.31 (-0.29)
Baxter Submits Application for U.S. FDA Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A
Business Wire - Mon Dec 01, 8:00AM CST
Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
BAX: 71.77 (-1.34), NKTR: 15.31 (-0.29)
Nektar Therapeutics (NKTR): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 7:49AM CST
Nektar Therapeutics might be an intriguing choice for investors as it is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.
NKTR: 15.31 (-0.29)
Shares of NKTR Up 15.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 26, 9:17AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 4 weeks, Nektar Therapeutics has returned 15.48% as of today's recent price of $15.85.
NKTR: 15.31 (-0.29)
Will Nektar Therapeutics (NKTR) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 7:33AM CST
Will Nektar Therapeutics (NKTR) Continue to Surge Higher?
NKTR: 15.31 (-0.29)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Nektar Therapeutics Is Up 8.2% (NKTR)
Comtex SmarTrend(R) - Mon Nov 24, 9:29AM CST
When Nektar Therapeutics (NASDAQ:NKTR) reported earnings two weeks ago on November 6th, 2014, analysts, on average, expected the company to report earnings of $0.41 on sales of $123.0 million. Nektar Therapeutics actually reported earnings of $0.53 per share on sales of $132.9 million, beating EPS estimates by $0.12 and beating revenue estimates by $9.9 million. Since the company's report, shares of Nektar Therapeutics have risen from $13.56 to $14.67, representing a gain of 8.2% in the past 18 days.
NKTR: 15.31 (-0.29)
FDA Grants QIDP Designation to Bayer's Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation
PR Newswire - Mon Nov 24, 9:12AM CST
The U.S. Food and Drug Administration (FDA) has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI). The QIDP designation was established as part of the Generating Antibiotic Incentives Now (GAIN) Act, passed by the US Congress in July 2012 to encourage pharmaceutical companies to develop new antimicrobial drugs. Antimicrobial drugs designed to treat serious and life-threatening infections, designated as QIDP, are eligible for fast-track designation, priority review by FDA and a five-year extension of market exclusivity. Amikacin Inhale is being developed by Bayer HealthCare in collaboration with Nektar Therapeutics (NASDAQ: NKTR).
NKTR: 15.31 (-0.29)
Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model
PR Newswire - Thu Nov 20, 8:00AM CST
Nektar Therapeutics (NASDAQ: NKTR) today announced results of a study investigating the preclinical anti-tumor activity and tolerability of etirinotecan pegol (NKTR-102) in combination with the PARP inhibitor rucaparib in a BRCA1-deficient MX-1 breast tumor model. The preclinical study results demonstrated that all dose combinations of NKTR-102 and rucaparib were well-tolerated, synergistic, and led to 100% prolonged survival in this tumor model. These data were presented during the Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, sponsored by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR).
NKTR: 15.31 (-0.29)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 10.64 (+0.42), INO: 8.49 (+0.27), ADXS: 3.78 (+0.14), GSK: 42.42 (-0.93), NKTR: 15.31 (-0.29), NVS: 93.52 (-0.82)